论文部分内容阅读
总结国内外关于紫杉类化疗药物对肿瘤免疫调节作用的研究进展。方法:应用Medline和CHKD期刊全文数据库检索系统,以“紫杉醇/多西紫杉醇,免疫调节,免疫治疗,化疗,肿瘤”为关键词,检索1999-01-2009-04紫杉类化疗药与免疫及肿瘤免疫治疗相关的文献,其中英文146篇,中文11篇,根据研究内容为紫杉醇或多西紫杉醇的免疫影响以及在肿瘤免疫治疗中的作用对文献进行筛选,最后纳入20篇。结果:紫杉类化疗药物具有明显的免疫调节作用,其抗肿瘤免疫调节作用与剂量和细胞亚群及作用时间相关。当紫杉类化疗药物与疫苗合理联合应用时可产生明显的抗肿瘤协同效果,紫杉类化疗药物具体的作用机制尚未完全明确。结论:化疗联合免疫疗法为肿瘤治疗带来了新的思路及希望,但目前紫杉类药物联合免疫治疗的研究尚处于初期,具体的机制及理想的联合方式仍需进一步研究。
Summarizes the domestic and foreign research on the taxane chemotherapeutic drugs on tumor immune regulatory role. Methods: Using the Medline and CHKD full-text database retrieval system and the key words of “paclitaxel / docetaxel, immunomodulatory, immunotherapy, chemotherapy and tumor” Immune and tumor immunotherapy related literature, of which 146 in English, 11 in Chinese, according to the contents of the study for the immune effects of paclitaxel or docetaxel and the role in tumor immunotherapy to screen the literature, and finally included 20 articles. Results: Taxanes chemotherapeutic drugs had obvious immunomodulatory effects. The anti-tumor immunomodulatory effects were related to dose, cell subpopulation and time of action. When the taxane chemotherapeutic agents and vaccines can be applied in a reasonable combination of anti-tumor synergistic effect can be obvious, the specific mechanism of action of taxanes chemotherapy drugs is not yet fully clear. Conclusion: Chemotherapy combined immunotherapy brings new ideas and hopes for cancer treatment. However, the current research on the combination immunotherapy of taxanes is still in its infancy. The specific mechanism and ideal combination still need further study.